Precigen's stock surged 8.19% in post-market trading on Wednesday, following the release of its first-quarter 2026 financial results.

The biopharmaceutical company reported revenue of $23.25 million, significantly beating analyst estimates of $20.80 million. This represents a dramatic increase of over 1,600% from $1.34 million in the same period last year, driven primarily by $21.6 million in sales from its newly launched product PAPZIMEOS. The product's commercial launch followed FDA approval in August 2025.

Precigen also reported a sharply narrowed net loss of $7.93 million compared to $54.2 million a year earlier. Management indicated that current cash reserves combined with anticipated PAPZIMEOS revenue should fund operations to cash flow break-even by the end of 2026, providing positive forward guidance to investors. Analyst sentiment remains bullish with a median price target of $9.50, representing significant upside potential.